Trial Profile
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Registrational; Therapeutic Use
- Acronyms ZOE-HSCT; ZOSTER-002
- Sponsors GlaxoSmithKline; GSK
- 28 Jun 2022 According to a GlaxoSmithKline media release, based on data from six clinical trials (NCT01610414, NCT01798056, NCT01767467, NCT00920218, NCT01165203), the company has submitted regulatory application to the Japanese MHLW for Shingrix for the prevention of shingles in adults aged 18 years and older who are at increased risk. This includes individuals with immunodeficiency or immunosuppression caused by known disease or therapy.
- 25 Oct 2020 Results assessing vaccine efficacy (VE) of the adjuvanted recombinant zoster vaccine from NCT01165177, NCT01165229 and NCT01610414 presented at the IDWeek 2020.
- 07 Oct 2018 Results presented at the IDWeek 2018